Developer docs
API playgroundTry for free, no card

Search company profiles

ALung Technologies

Full company profile

uuid0002nah

Namestring
ALung Technologies
Legal namestring
LivaNova PLC
Websiteurl
alung.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

ALung Technologies is a private, for-profit medical device company founded in 1997 and headquartered in Pittsburgh, Pennsylvania. The company develops medical gas exchange devices intended for the treatment of acute and chronic respiratory disorders, built around proprietary perfusion technology for cardiopulmonary applications. The input identifies a proprietary "Continuous Perfusion Sensing Technology" tied to novel method/architecture innovation in pediatric perfusion device design, positioning ALung as a participant — alongside Medtronic, LivaNova, and Edwards Lifesciences — in the broader cardiopulmonary medical device landscape, with a stated emphasis on the pediatric perfusion subsegment.

The company's go-to-market orientation is B2B, targeting healthcare institutions and providers specializing in pediatric cardiac and perfusion care. Pricing and revenue model details are not publicly disclosed in the available sources, and no named end-customer logos are present in the input. The company has maintained a small operating footprint of 11–50 employees, with leadership weighted toward regulatory, quality, and scientific affairs expertise — consistent with a company focused on regulated medical device development and clinical pathway execution rather than scaled commercial deployment.

ALung has financed its development through approximately $112.9M in disclosed funding across eleven rounds from 2009 through November 2020, with the 2017 round ($36M, co-led by Philips Healthcare and UPMC) representing the company's most significant capital event and the closest indication of strategic OEM validation. Cumulative funding, headcount scale, and the absence of disclosed revenue or post-2020 capital activity indicate a company that has not yet reached scaled commercialization as represented in the input data.

Short descriptiontext

ALung Technologies develops medical gas exchange devices for acute and chronic respiratory disorders using proprietary perfusion technology, serving pediatric healthcare institutions. Founded in 1997 in Pittsburgh, it competes alongside Medtronic, LivaNova, and Edwards Lifesciences in the cardiopulmonary device market.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPittsburgh, United States
HQ citystring
Pittsburgh
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
extracorporeal gas exchange, respiratory assist devices, perfusion technology, cardiopulmonary medical devices, carbon dioxide removal
Industry2 codes
PRIMARYHLAHAGAC
Ventilators & Mechanical Ventilation Systems (ICU/Transport/Home)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHAGAK
Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
NAICS code2 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Respiratory Medical Devices
Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1VNS Therapy
Description

Vagus Nerve Stimulation therapy for epilepsy and depression treatment

livanova.com
+3 more records
Core offering1 text field

ALung Technologies develops medical gas exchange devices used in the treatment of acute and chronic respiratory disorders. The company's core work centers on perfusion-based cardiopulmonary medical devices, including advanced continuous perfusion sensing technology, targeted at hospitals and clinicians managing severe respiratory failure.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Medical Gas Exchange Devices
CategoryRespiratory Medical Devices
Description

Medical devices designed to perform extracorporeal gas exchange for patients with acute and chronic respiratory disorders, used by hospitals and clinicians managing severe respiratory failure.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

LivaNova is a global medical device company with a dedicated cardiopulmonary business (Essenz Perfusion System) that directly competes with ALung in perfusion and extracorporeal gas exchange devices used in cardiac surgery and respiratory support. ALung's own profile lists LivaNova as a fellow leader in the pediatric perfusion market.

TypeBroad incumbent
Description

Medtronic is one of the world's largest medical device companies with a significant perfusion and cardiopulmonary portfolio (including its legacy Covidien perfusion business). It is named alongside ALung as a leader in the pediatric perfusion market and competes across perfusion, oxygenation, and related cardiopulmonary support.

TypeBroad incumbent
Description

Edwards Lifesciences is a major cardiac and critical care medtech player with established products in hemodynamic monitoring and perfusion-adjacent technologies. It is named alongside ALung as a leader in the pediatric perfusion market and overlaps in cardiopulmonary support for cardiac surgery.

TypeDirect peer
Description

Abiomed (a Johnson & Johnson MedTech company) develops percutaneous and extracorporeal circulatory support devices such as Impella and Breethe. It is a strategic investor in ALung and competes in the broader cardiopulmonary and mechanical circulatory support space relevant to ALung's gas exchange technology.

TypeBroad incumbent
Description

Getinge, through its Maquet brand, is a global leader in cardiopulmonary products including heart-lung machines, oxygenators, and ECMO systems. It directly overlaps with ALung in extracorporeal gas exchange and perfusion technology for cardiac surgery and ICU respiratory support.

6Terumo Cardiovascular
TypeDirect peer
Description

Terumo Cardiovascular manufactures perfusion systems, oxygenators, and related cardiopulmonary products used in cardiac surgery. It is one of the closest direct competitors to ALung in extracorporeal gas exchange and perfusion hardware.

TypeDirect peer
Description

Xenios AG, part of Fresenius Medical Care, develops ECMO and ECCO2R systems (e.g., i-cor, Hilite) used for extracorporeal lung and cardiac support. It competes with ALung's Hemolung-style gas exchange technology in respiratory and cardiac failure indications.

8Nipro Medical Corporation
TypeRegional player
Description

Nipro manufactures oxygenators, perfusion circuits, and dialysis-related equipment. While strongest in Japan and parts of Asia, it competes globally with ALung in cardiopulmonary disposables and extracorporeal support products.

TypeEmerging player
Description

Inspira Technologies is an emerging medical device company developing extracorporeal blood oxygenation and respiratory support systems. Its technology focus on direct blood oxygenation overlaps with ALung's gas exchange platform, making it a relevant emerging competitor.

TypeEmerging player
Description

CytoSorbents develops extracorporeal blood purification technologies used in critical care, including for patients with respiratory failure. Its technology and clinical positioning in ICU blood/气体 exchange adjacencies make it a relevant emerging peer to ALung's extracorporeal platform.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ALung Technologies

Respiratory Medical Devicesalung.com

ALung Technologies develops medical gas exchange devices for acute and chronic respiratory disorders using proprietary perfusion technology, serving pediatric healthcare institutions. Founded in 1997 in Pittsburgh, it competes alongside Medtronic, LivaNova, and Edwards Lifesciences in the cardiopulmonary device market.

What ALung Technologies does

ALung Technologies is a private, for-profit medical device company founded in 1997 and headquartered in Pittsburgh, Pennsylvania. The company develops medical gas exchange devices intended for the treatment of acute and chronic respiratory disorders, built around proprietary perfusion technology for cardiopulmonary applications. The input identifies a proprietary "Continuous Perfusion Sensing Technology" tied to novel method/architecture innovation in pediatric perfusion device design, positioning ALung as a participant — alongside Medtronic, LivaNova, and Edwards Lifesciences — in the broader cardiopulmonary medical device landscape, with a stated emphasis on the pediatric perfusion subsegment.

The company's go-to-market orientation is B2B, targeting healthcare institutions and providers specializing in pediatric cardiac and perfusion care. Pricing and revenue model details are not publicly disclosed in the available sources, and no named end-customer logos are present in the input. The company has maintained a small operating footprint of 11–50 employees, with leadership weighted toward regulatory, quality, and scientific affairs expertise — consistent with a company focused on regulated medical device development and clinical pathway execution rather than scaled commercial deployment.

ALung has financed its development through approximately $112.9M in disclosed funding across eleven rounds from 2009 through November 2020, with the 2017 round ($36M, co-led by Philips Healthcare and UPMC) representing the company's most significant capital event and the closest indication of strategic OEM validation. Cumulative funding, headcount scale, and the absence of disclosed revenue or post-2020 capital activity indicate a company that has not yet reached scaled commercialization as represented in the input data.

ALung Technologies firmographics

Firmographics
Name
ALung Technologies
Legal name
LivaNova PLC
Website
https://alung.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
ALung Technologies develops medical gas exchange devices for acute and chronic respiratory disorders using proprietary perfusion technology, serving pediatric healthcare institutions. Founded in 1997 in Pittsburgh, it competes alongside Medtronic, LivaNova, and Edwards Lifesciences in the cardiopulmonary device market.
Ownership category
akta.pro rank

ALung Technologies industry classification

Industry
Product category
Respiratory Medical Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAGAC
Ventilators & Mechanical Ventilation Systems (ICU/Transport/Home)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHAGAK
Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices

Keywords

  • Extracorporeal gas exchange
  • Respiratory assist devices
  • Perfusion technology
  • Cardiopulmonary medical devices
  • Carbon dioxide removal

Where ALung Technologies is headquartered

Location

Headquarters

HQ city
Pittsburgh
HQ country
United States
HQ region
North America

Markets served

ALung Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

ALung Technologies product offering

Product offering

Core offering

ALung Technologies develops medical gas exchange devices used in the treatment of acute and chronic respiratory disorders. The company's core work centers on perfusion-based cardiopulmonary medical devices, including advanced continuous perfusion sensing technology, targeted at hospitals and clinicians managing severe respiratory failure.

Differentiator

Problem solved

Functional benefit

Brands

  • VNS Therapy: Vagus Nerve Stimulation therapy for epilepsy and depression treatment
  • Essenz Perfusion System
  • Sentiva
  • Symmetry

Products and services

  • Medical Gas Exchange Devices Medical devices designed to perform extracorporeal gas exchange for patients with acute and chronic respiratory disorders, used by hospitals and clinicians managing severe respiratory failure.

Companies that use ALung Technologies

Customer profile

Segments1 record

Ideal customer profiles1 record

ALung Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

ALung Technologies partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights3 records

ALung Technologies competitors and assessment

Company assessment

Direct peers

  • LivaNova PLC: LivaNova is a global medical device company with a dedicated cardiopulmonary business (Essenz Perfusion System) that directly competes with ALung in perfusion and extracorporeal gas exchange devices used in cardiac surgery and respiratory support. ALung's own profile lists LivaNova as a fellow leader in the pediatric perfusion market.
  • Abiomed: Abiomed (a Johnson & Johnson MedTech company) develops percutaneous and extracorporeal circulatory support devices such as Impella and Breethe. It is a strategic investor in ALung and competes in the broader cardiopulmonary and mechanical circulatory support space relevant to ALung's gas exchange technology.
  • Terumo Cardiovascular: Terumo Cardiovascular manufactures perfusion systems, oxygenators, and related cardiopulmonary products used in cardiac surgery. It is one of the closest direct competitors to ALung in extracorporeal gas exchange and perfusion hardware.
  • Xenios AG (Fresenius Medical Care): Xenios AG, part of Fresenius Medical Care, develops ECMO and ECCO2R systems (e.g., i-cor, Hilite) used for extracorporeal lung and cardiac support. It competes with ALung's Hemolung-style gas exchange technology in respiratory and cardiac failure indications.

Broad incumbents

  • Medtronic: Medtronic is one of the world's largest medical device companies with a significant perfusion and cardiopulmonary portfolio (including its legacy Covidien perfusion business). It is named alongside ALung as a leader in the pediatric perfusion market and competes across perfusion, oxygenation, and related cardiopulmonary support.
  • Edwards Lifesciences: Edwards Lifesciences is a major cardiac and critical care medtech player with established products in hemodynamic monitoring and perfusion-adjacent technologies. It is named alongside ALung as a leader in the pediatric perfusion market and overlaps in cardiopulmonary support for cardiac surgery.
  • Getinge (Maquet): Getinge, through its Maquet brand, is a global leader in cardiopulmonary products including heart-lung machines, oxygenators, and ECMO systems. It directly overlaps with ALung in extracorporeal gas exchange and perfusion technology for cardiac surgery and ICU respiratory support.

Regional players

  • Nipro Medical Corporation: Nipro manufactures oxygenators, perfusion circuits, and dialysis-related equipment. While strongest in Japan and parts of Asia, it competes globally with ALung in cardiopulmonary disposables and extracorporeal support products.

Emerging players

  • Inspira Technologies: Inspira Technologies is an emerging medical device company developing extracorporeal blood oxygenation and respiratory support systems. Its technology focus on direct blood oxygenation overlaps with ALung's gas exchange platform, making it a relevant emerging competitor.
  • CytoSorbents Corporation: CytoSorbents develops extracorporeal blood purification technologies used in critical care, including for patients with respiratory failure. Its technology and clinical positioning in ICU blood/气体 exchange adjacencies make it a relevant emerging peer to ALung's extracorporeal platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

ALung Technologies social profiles

Digital presence

ALung Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ALung Technologies leadership team

Management profile

Number of profiles

Profiles7 records

ALung Technologies funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ALung Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ALung Technologies

What does ALung Technologies do?

ALung Technologies develops medical gas exchange devices used in the treatment of acute and chronic respiratory disorders. The company's core work centers on perfusion-based cardiopulmonary medical devices, including advanced continuous perfusion sensing technology, targeted at hospitals and clinicians managing severe respiratory failure.

Is ALung Technologies a public or private company?

ALung Technologies is a public company. It is classified as venture growth investor backed and is currently operating.

When was ALung Technologies founded?

ALung Technologies was founded in 2015. It employs 11 to 50 people.

Where is ALung Technologies based?

ALung Technologies is headquartered in Pittsburgh, United States, in the North America region.

Who are ALung Technologies's main competitors?

Direct peers on record are LivaNova PLC, Abiomed, Terumo Cardiovascular and Xenios AG (Fresenius Medical Care). Broad incumbents are Medtronic, Edwards Lifesciences and Getinge (Maquet). Nipro Medical Corporation is listed as a regional player. Emerging players are Inspira Technologies and CytoSorbents Corporation.

Does ALung Technologies have an API?

No public API is recorded for ALung Technologies.

What industry is ALung Technologies in?

ALung Technologies's product category is Respiratory Medical Devices. Its primary akta.pro industry code is HLAHAGAC, Ventilators & Mechanical Ventilation Systems (ICU/Transport/Home), with a secondary code of HLAHAGAK, Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American City Business Journals2022 Fire Awards, Exits of the Year: ALung TechnologiesLivaNova PLC acquired ALung Technologies for $10 million in May, with additional payments tied to sales-based milestones. The deal was announced in May, with the exact amount subject to future milestones.Pittsburgh Post-GazetteLondon-based LivaNova is picking up another Pittsburgh biotech firmLondon-based LivaNova PLC is acquiring the remaining 97% equity interest in Pittsburgh biotech firm ALung Technologies Inc. for $10 million plus milestone payments, as disclosed in its first-quarter financials. This transaction follows LivaNova's 2018 acquisition of CardiacAssist and builds upon ALung's recent FDA approval for its artificial lung device.Mpo-magALung Announces Commercial Development of its Next-Generation Artificial LungALung Technologies announced the initiation of commercial development of its next-generation Hemolung RAS artificial lung, based on licensed University of Pittsburgh technology. The system aims to enhance gas exchange efficiency and reduce hematologic effects, with features including a custom centrifugal pump and low surface area membrane. It will support both low-flow ECCO2R and full ECMO.PR NewswireWorldwide Artificial Lung Devices in the Pipeline, 2020 - Product Profiles, Major Players, Clinical Trials, Recent DevelopmentsResearchAndMarkets.com announced the release of a market research report titled "Artificial Lung - Medical Devices Pipeline Assessment, 2020," providing an overview of artificial lung devices in development stages along with profiles of major players and clinical trial information. The report's recent developments section noted that Alung Technologies achieved key milestones in its U.S.-based Vent-AVOID clinical trial in 2019, with the independent Data and Safety Monitoring Board recommending continuation of the trial. Companies covered in the report include ALung Technologies Inc., Breethe Inc., Lung Biotechnology PBC, Miromatrix Medical Inc., and several academic and research institutions.PR NewswireExtracorporeal CO2 Removal Market to be Worth US$ 110.0 Mn by 2026, Says TMRTransparency Market Research published a report projecting the global extracorporeal CO2 removal market to reach US$ 110.0 million by 2026, growing at a 6.0% CAGR from 2018 to 2026. The growth is driven by rising demand for minimally invasive ventilation technologies and increasing prevalence of respiratory diseases like COPD and ARDS. Key manufacturers such as ALung Technologies and Xenios AG are expected to benefit from this expansion, particularly in North America and Europe.VC News DailyALung Technologies Nets $36M Series CALung Technologies closed a $36 million Series C financing round led by Philips and UPMC Enterprises to support US-based pivotal trials for FDA approval of its Hemolung Respiratory Assist System. The investment includes board seats for representatives from Philips and UPMC, alongside participation from other investors such as Abiomed. This funding marks a critical step in bringing the artificial lung device to the United States market after successful treatments abroad.MedCity NewsALung brings in $12M to move forward with approval of its artificial lungALung Technologies raised $12 million from wealthy investors in Western Pennsylvania to advance its artificial lung, Hemolung RAS, toward U.S. FDA approval. The device, already sold in Europe since 2014, is expected to receive clearance by 2018 or 2019.VC News DailyALung Technologies Raises $10MALung Technologies, a Pittsburgh-based medical device company, has closed approximately $10 million in new financing from new and existing investors to support commercialization of its Hemolung Respiratory Assist System. The Hemolung RAS is the world's first low-flow extracorporeal carbon dioxide removal system for critically ill patients with acute respiratory failure, currently approved in 29 countries across Europe, the Middle East, and Asia-Pacific, with commercial roll-out underway in Germany, the UK, France, Canada, and Australia. The device has been validated at 43 hospitals in 13 countries, with therapy utilization increasing quarter over quarter.VC News DailyALung Technologies Inhales $15.8M Series B-1ALung Technologies, a Pittsburgh-based developer of respiratory assist devices, announced the closing of a $15.8 million Series B-1 financing round led by Allos Ventures with participation from West Capital Partners, Birchmere Ventures, BlueTree Capital Group, PLSG Accelerator Fund, Smithfield Trust Company, and additional private investors. The funding will support global commercialization of the Hemolung Respiratory Assist System and development of next-generation extracorporeal lung support products, with the company having raised a total of $56 million in equity capital to date. The Hemolung RAS, approved for sale in Europe and Canada, is positioned to address an estimated $4 billion ECCO2R market as ALung expands its direct commercial operations in Germany, France, and the United Kingdom.VC News DailyALung Technologies Inhales $10M in Series BALung Technologies, a Pittsburgh-based developer of advanced respiratory products, has closed a $10 million Series B financing round with participation from existing shareholders, Eagle Ventures, and Birchmere Ventures. The funding will support commercialization of the company's Hemolung Respiratory Assist System, which recently completed a 20-patient clinical trial in Germany, with results currently under regulatory review for European CE mark approval.